Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
NGO · Netherlands
Declared costs: not declared · in the register since 2016
Industry association · Belgium
Declared costs: €1.5M+ a year · in the register since 2008
Medicinal products for human use · Revision of the EU legislation on medicines for children and rare diseases
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
European Fair Pricing Network · filed 22 Apr 2021 · source
The European Fair Pricing Network (EFPN) welcomes the Commission’s initiative to revise the EU general pharmaceutical legislation. The EFPN urges the Commission to prioritize the following problems: First, unequal access to affordable medicines for patients EU wide is a great problem that threatens the health and lives of many Europeans.
American Chamber of Commerce to the EU · filed 27 Apr 2021 · source
The American Chamber of Commerce to the EU (AmCham EU) is committed to the development of a regulatory environment which furthers the capabilities of European healthcare, improving accessibility and ensuring a crisis-resistant medicines regulatory system.
American Chamber of Commerce to the EU · filed 6 Nov 2023 · source
Introduction To be truly future proof and innovation friendly, the EU's proposed pharmaceutical package must address the blocs declining attractiveness for investment. We therefore urge EU co-legislators to secure globally competitive incentives for research and development (R&D) and avoid additional unnecessary administrative burdens on companies.
American Chamber of Commerce to the EU · filed 6 Nov 2023 · source
Introduction To be truly future proof and innovation friendly, the EU's proposed pharmaceutical package must address the blocs declining attractiveness for investment. We therefore urge EU co-legislators to secure globally competitive incentives for research and development (R&D) and avoid additional unnecessary administrative burdens on companies.
European Fair Pricing Network · filed 15 Dec 2020 · source
European Fair Pricing Network - EFPN The European Fair Pricing Network (EFPN) welcomes the Commission’s initiative to seek a new legal framework to solve issues within current legislation on medicines for children and rare diseases. The EFPN urges the Commission to prioritise the following problems: First, there are no approved treatments for 95% of rare diseases. This must change.
American Chamber of Commerce to the EU · filed 6 Jan 2021 · source
Representing American companies operating in the EU, AmCham EU is well aware of the differences and respective strengths of innovation ecosystems on both sides of the Atlantic. The options laid out in the inception impact assessment (IIA) risk undermining an EU framework that has proven largely successful, rather than preserving the EU’s strengths and incorporating learnings from other regions.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.